NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10618088		
	Filing Date		2003-07-14		
	First Named Inventor Elizab		beth JAFFE		
	Art Unit		1643		
	Examiner Name	Gussi	ow, Anne		
	Attorney Docket Numb	er	001107.00363		

					0.3.	PAIENIS			Homoro	1	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment				
	1										
If you wisl	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*			Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Releva			s,Columns,Lines where vant Passages or Relevant es Appear		
	1										
If you wisl	h to ad	d additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*				Country Kind Code ² i Cod		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		т.
	1										
If you wis	h to ad	d additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	1-PATEN	IT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), nublisher city, and/or country where published.								T5			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10618088		
Filing Date		2003-07-14		
First Named Inventor	Elizat	Elizabeth JAFFE		
Art Unit		1643		
Examiner Name	Gussow, Anne			
Attorney Docket Number		001107.00363		

	1	BODEY, SIEGEL, and KAISER. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Research, 2000. Vol. 20, pages 2655-2676.			
	2	LEE, WANG, NELSEN, WUNDERLICH, MIGUELES, CONNORS, STEINBERG, ROSENBERG, and MARINCOLA. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. Journal of Immunology, 1999, Vol. 163, pages 6292-6300.			
	3	FORNI, LOLLINI, MUSIANI, and COLOMBO. Immunoprevention of cancer, is the time ripe? Cancer Research, 2000. Vol. 60, pages 2571-2575.			
	4	GURA. Systems for identifying new drugs are often faulty. Science, 1997. Vol. 278, pages 1041-1042.			
	5	DE GRUUL and CURIEL. Cancer vaccine strategies get bigger and better. Nature Medicine, 1999. Vol. 5, pages 1124-1125.			
	6	CHATTERJEE, FOON, and KOHLER. kilotysis anabody mmunotherapy of cancer. Cancer immunology Immunotherapy, 1994. Vol. 38, pages 75-82.			
	7	Non-Final Office Action dated March 10, 2010 in co-pending U.S. Patent Application No. 12/210,604.			
If you wish to add additional non-patent literature document citation information please click the Add button Add					

Examiner Signature Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.